Movement Alert｜Gilead Sciences Rises 3.07% in Regular Trading, $7.8 Billion Arcellx Acquisition Combined with Q2 Beat Continues to Lift Shares

Market Focus08-21 23:47

On August 21, Gilead Sciences rose 3.07% in regular trading, trading at $147.85 per share, with turnover of $228 million. The stock has maintained upward momentum since the company announced a major acquisition earlier this week.

On August 18, Gilead Sciences announced the acquisition of cancer therapy developer Arcellx at an equity value of $7.8 billion, offering $115 per share in cash plus $5 per share in contingent value rights, representing an 87% premium to Arcellx's prior closing price. The market views this as a significant strategic move to further strengthen Gilead's oncology pipeline, and the deal has continued to buoy investor sentiment since its announcement.

Adding to the positive momentum, Gilead's Q2 results reported on August 4 showed revenue of $7.8 billion, exceeding the $7.4 billion analyst consensus. Full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, meaningfully better than the FactSet estimate of $0.75 loss. The company also raised its full-year HIV business growth outlook to 9%-10%, up from the prior 8% guidance, reflecting continued operational strength in its core franchise.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167348734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-21 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167348734","market":"us","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Rises 3.07% in Regular Trading, $7.8 Billion Arcellx Acquisition Combined with Q2 Beat Continues to Lift Shares","media":"Market Focus","content":"<p><p>On August 21, Gilead Sciences rose 3.07% in regular trading, trading at $147.85 per share, with turnover of $228 million. The stock has maintained upward momentum since the company announced a major acquisition earlier this week.</p><p>On August 18, Gilead Sciences announced the acquisition of cancer therapy developer Arcellx at an equity value of $7.8 billion, offering $115 per share in cash plus $5 per share in contingent value rights, representing an 87% premium to Arcellx's prior closing price. The market views this as a significant strategic move to further strengthen Gilead's oncology pipeline, and the deal has continued to buoy investor sentiment since its announcement.</p><p>Adding to the positive momentum, Gilead's Q2 results reported on August 4 showed revenue of $7.8 billion, exceeding the $7.4 billion analyst consensus. Full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, meaningfully better than the FactSet estimate of $0.75 loss. The company also raised its full-year HIV business growth outlook to 9%-10%, up from the prior 8% guidance, reflecting continued operational strength in its core franchise.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Rises 3.07% in Regular Trading, $7.8 Billion Arcellx Acquisition Combined with Q2 Beat Continues to Lift Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Rises 3.07% in Regular Trading, $7.8 Billion Arcellx Acquisition Combined with Q2 Beat Continues to Lift Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-21 23:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 21, Gilead Sciences rose 3.07% in regular trading, trading at $147.85 per share, with turnover of $228 million. The stock has maintained upward momentum since the company announced a major acquisition earlier this week.</p><p>On August 18, Gilead Sciences announced the acquisition of cancer therapy developer Arcellx at an equity value of $7.8 billion, offering $115 per share in cash plus $5 per share in contingent value rights, representing an 87% premium to Arcellx's prior closing price. The market views this as a significant strategic move to further strengthen Gilead's oncology pipeline, and the deal has continued to buoy investor sentiment since its announcement.</p><p>Adding to the positive momentum, Gilead's Q2 results reported on August 4 showed revenue of $7.8 billion, exceeding the $7.4 billion analyst consensus. Full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, meaningfully better than the FactSet estimate of $0.75 loss. The company also raised its full-year HIV business growth outlook to 9%-10%, up from the prior 8% guidance, reflecting continued operational strength in its core franchise.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1167348734","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167348734","pubTimestamp":1787327233,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 21, Gilead Sciences rose 3.07% in regular trading, trading at $147.85 per share, with turnover of $228 million. The stock has maintained upward momentum since the company announced a major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势警报|吉利德科学常规交易上涨 3.07%，78 亿美元收购 Arcellx 加上第二季度业绩继续提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On August 21, Gilead Sciences rose 3.07% in regular trading, trading at $147.85 per share, with turnover of $228 million. The stock has maintained upward momentum since the company announced a major acquisition earlier this week.On August 18, Gilead Sciences announced the acquisition of cancer therapy developer Arcellx at an equity value of $7.8 billion, offering $115 per share in cash plus $5 per share in contingent value rights, representing an 87% premium to Arcellx's prior closing price. The market views this as a significant strategic move to further strengthen Gilead's oncology pipeline, and the deal has continued to buoy investor sentiment since its announcement.Adding to the positive momentum, Gilead's Q2 results reported on August 4 showed revenue of $7.8 billion, exceeding the $7.4 billion analyst consensus. Full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, meaningfully better than the FactSet estimate of $0.75 loss. The company also raised its full-year HIV business growth outlook to 9%-10%, up from the prior 8% guidance, reflecting continued operational strength in its core franchise.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167348734","isCrawlerRequest":true}